Provided by Tiger Trade Technology Pte. Ltd.

iBio

1.36
-0.0400-2.86%
Post-market: 1.390.0291+2.14%19:30 EDT
Volume:521.25K
Turnover:712.14K
Market Cap:67.56M
PE:-2.43
High:1.42
Open:1.42
Low:1.34
Close:1.40
52wk High:3.82
52wk Low:0.7708
Shares:49.68M
Float Shares:34.88M
Volume Ratio:1.11
T/O Rate:1.49%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5600
EPS(LYR):-1.7504
ROE:-65.70%
ROA:-30.80%
PB:0.79
PE(LYR):-0.78

Loading ...

iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update

GlobeNewswire
·
May 13

iBio Inc expected to post a loss of 6 cents a share - Earnings Preview

Reuters
·
May 08

iBio names Elizabeth Stoner to board as Schimmelpennink steps down

Reuters
·
May 08

Ibio Appoints Distinguished Biotech Leader, Elizabeth Stoner, to Its Board of Directors

THOMSON REUTERS
·
May 08

Press Release: iBio Appoints Distinguished Biotech Leader, Elizabeth Stoner, to its Board of Directors

Dow Jones
·
May 08

iBio Inc expected to post a loss of 6 cents a share - Earnings Preview

Reuters
·
Apr 28

iBio amends 8-K to correct Series G warrants expiration date to May 20, 2026

Reuters
·
Apr 18

iBio Is Maintained at Buy by Chardan Capital

Dow Jones
·
Apr 09

Ibio (IBIO) Receives a Buy from Chardan Capital

TIPRANKS
·
Apr 09

Validating iBio’s Antibody Platform: Buy Rating Driven by IBIO-600’s Differentiated Obesity Profile and Long-Acting Myostatin Inhibition

TIPRANKS
·
Apr 09

BUZZ-U.S. STOCKS ON THE MOVE-Delta, GATX, Humana

Reuters
·
Apr 08

iBio receives regulatory clearance to initiate IBIO-600 trial in Australia

TIPRANKS
·
Apr 08

BUZZ-iBio rises as obesity drug gets first green light for human trial in Australia

Reuters
·
Apr 08

iBio wins Australian TGA clearance for Phase 1 IBIO-600 trial

Reuters
·
Apr 08

Ibio Inc - Phase 1 Trial of Ibio-600 to Begin Dosing in Q2 2026

THOMSON REUTERS
·
Apr 08

iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia

GlobeNewswire
·
Apr 08

Impact BioMedical Inc. Reports Going Concern Audit Opinion in 2025 10-K Filing While Continuing Strategic Merger Plans

GlobeNewswire
·
Apr 04

iBio Chief Legal Officer Marc Banjak acquires common shares; $23,028 value

Reuters
·
Mar 28

iBio (IBIO-610): Validated Activin E Mechanism, Strategic Trial Positioning, and Attractive Risk-Reward Support a Buy Rating

TIPRANKS
·
Mar 27

iBio CFO Felipe Duran buys USD 50,000 of common shares

Reuters
·
Mar 23